CEO Today Business Women of the Year Awards

www.ceotodaymagazine.com 56 CEO Today Business Women of the Year Awards 2018 USA LORAINE UPHAM Chief Operating Officer of Boston Therapeutics, Inc. FIRM PROFILE Boston Therapeutics, Inc. (OTCQB:BTHE) is a pre-clinical and clinical- stage BioPharmaceutical company focused on the development and commercialization of novel carbohydrate-based materials and peptide compounds, for unmet medical needs in the area of metabolism. With offices in Lawrence, MA, Albuquerque, NM, and Hong Kong, Boston Therapeutics is a global company focused on the development, contract manufacture and commercialization of carbohydrate-based materials as supplements and drugs, and peptide therapeutic drugs. All products are designed to help manage blood sugar, pre-diabetes, diabetes, and diabetes related pathologies. Our Story Boston Therapeutics, began as a leader in the field of complex carbohydrate chemistry and through the acquisition of CureDM, acquired a Phase II ready peptide-based therapeutic for the treatment of type 1 and type 2 diabetes. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for sugar control, more specifically prediabetics and diabetes. Investigative material BTI- 320, a non-systemic formulation, is designed to reduce post-meal glucose elevation. A commercially available food supplement based on similar non- systemic carbohydrate material, SUGARDOWN®, has progressed into market testing as a dietary supplement designed to manage post-meal sugar spikes. Both SUGARDOWN and BTI-320 are designed to reduce “post-meal elevation” of blood glucose levels in pre-diabetes patients and type 2 diabetes patients. Recently, with the acquisition of CureDM in the first quarter of 2018, a new investigative material BTI-410, an injectable peptide, is under development at Boston Therapeutics. Following a successful IND application in 2012, a Phase Ia First-in-Man study was completed in which ascending doses of BTI-410, appeared to be safe and well tolerated by all subjects in the study. A Phase Ib study entitled, “A Randomized, Double-blind, Placebo- controlled Study of the Effect of 49 days of Treatment with Repeated Subcutaneous Doses of HIP2B (BTI-410) to Assess Safety, Tolerability and Measures of islet β-cell Function in Subjects with Type 2 Diabetes Mellitus Treated with Metformin”, was completed in 2015 with statistically significant secondary endpoints. Two new pivotal clinical trials are planned for the study of BTI-410. According to Standard & Poor’s, the diabetes drug market is on pace to grow to more than $64 billion by 2025. Pharmaceutical companies have been investigating new approaches to treating diabetes and market value has been maintained in the industry due to the introduction of these new products. We believe that both BTI-320 and BTI-410 represents unique commercial opportunites in a large and growing diabetes market worldwide. ABOUT LORAINE UPHAM Boston Therapeutics’ Chief Operating Officer, Loraine V. Upham joined the company through the recent acquisition of the CureDM. Loraine was founding CEO of CureDM and took over again in 2016 to execute the transaction with Boston Therapeutics. In 2004, Loraine co-founded and secured the first $3.5 M in start-up funding that put CureDM on the biotech map. The company developed the peptide therapeutic from just an idea, through preclinical stages to a clinical Phase II ready compound. The CureDM peptide fits well with the Boston Therapeutics pipeline as another bold compound that can disrupt the marketplace of currently available diabetes treatments and potentially change the trajectory of metabolic diseases on a worldwide basis. Having obtained her BA in Biology from University of Pennsylvania, Loraine became a member of the Molecular Genetics Department at Eli Lilly and Co, where she worked on a number of protein expression projects. She obtained her MBA from Arizona state while she trained and then competed in the 1988 US Olympic Trials Marathon. She spent two years at Merck and Co and then joined Packard BioScience as an Applications Specialist and Product Manager to launch imaging systems and high throughput screening instruments and assays worldwide leading to its acquisition by Perkin Elmer in 2001. In 2002, just prior to co-founding CureDM, Loraine was a member of the Process Development and Management Teams at a proteomics start up, Prolexys Pharmaceuticals. Here she acquired skills that helped her to define the CureDM peptide. In 2015, she was appointed by the Governor of the State of New Mexico and continues to serve as a Member of the New Mexico Technology Research Collaborative. Today she is committed to the growth and development of Boston Therapeutics as a leader in the BioPharmaceutical industry. CONTACT E: Loraine.Upham@Bostonti.com W: www.BostonTI.com T: 603-935-9799